A handsome young man with headache, nausea and vomiting had a cranial MRI that revealed a glioma. Surgical pathology: glioblastoma, WHO grade IV. Preoperative imaging suggested: high-grade glioma of the corpus callosum in both frontal lobes (right frontal lobe predominant). The tumor volume was approximately 97 ml with the classical T1 enhancement sequence and approximately 212 ml with the T2 sequence. According to the current guidelines, complete resection of the enhanced portion on the T1 sequence is “perfect”. Postoperatively, adjuvant temozolomide is used in conjunction with radiotherapy. The probability of survival is 15-17 months. Based on the clinical practice of more resection for more benefit, we resected the tumor according to the T2 sequence for this patient, that is, from the guideline standard of 97 ml to 212 ml. Is 212 ml a tumor? The tumor cell density is greater than 500 cells/mm3 in order to show the abnormality on MRI, which means there must be tumor cells in the abnormal area. The normal area near the abnormal area also has tumor, but the cell density is lower. Therefore, the resected 212ml must be a tumor. The tumor cell distribution characteristics of high-grade glioma: In the core part of the tumor, the tumor cells have the highest density, the most obvious heterogeneity and the most active value-added; the further away from the core area, the lower the density of tumor cells, the less obvious heterogeneity and the less active value-added. Therefore, the larger the cut area is, the less tumor cells are left, and the remaining tumor cells are also inactive and less active in value-added. It is not known exactly how far there is no tumor left. Even if the tumor is cut according to the boundary of the yellow circle, it still cannot be cured. More cuts for more gains? A recent JAMA (2019 Impact Factor:22.416) study confirmed that for patients with glioblastoma aged <65 years, even those with IDH wild type, the median survival was about 37.3 months (3 years) with surgical resection of 100% of the enhancing portion + at least 90% of the non-enhancing portion, supplemented with postoperative temozolomide radiotherapy. In contrast, the median survival of patients with resection of only the enhancing portion was 15-17 months. Expanded resection doubled patient survival. In recent years, the T2Flair sequence has long been used as a target for glioma resection, with super-expansion if circumstances permit. For high-grade gliomas, there is a new consensus to conceptually consider the area of abnormalities on MRI as the extent of resection, rather than just the enhanced portion. Of course, safety (functional preservation) must be considered first. Sometimes it is not even possible to perform a complete resection of the enhancing portion in order to preserve function.